Mark Ellis

Mark Ellis currently serves as Lead at Brightly Network, focusing on the development of innovative medical communications tools. With extensive experience as Senior VP of Medical and Scientific Strategy at BluPrint Oncology, Mark manages teams that support various biotech and pharmaceutical companies. Former roles include Medical Director at BGB Group, where Mark provided strategic oversight for oncology medical teams, and Director of Scientific Strategy at E Squared Communications. Mark's foundational expertise in scientific strategy is backed by a PhD in Cell Biology and Molecular Physiology from the University of Pittsburgh and postdoctoral training at Columbia University. Mark has also contributed to academia through guest lectures on health policy and microbiology at The New School.